Phase 3 trial in 418 adults with moderately to severely active ulcerative colitis: subcutaneous guselkumab 400 mg induction gave week-12 clinical remission in 28% vs 6% with placebo (difference 21 points). Serious adverse events: 4% in each guselkumab group vs 12% placebo.
RCTn = 418
Long et al. Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial